Ultivue
Company

Last deal

$3.32M

Amount

Venture - Series Unknown

Stage

25.07.2024

Date

3

all rounds

$110.58M

Total amount

date founded

Financing round

General

About Company
Ultivue is a biotechnology company that produces reagents for tissue imaging and diagnostics.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2015

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

Ultivue's reagents enable researchers to obtain high-resolution microscopic images for fluorescent microscopy-based research, and their technology is used to elucidate biological pathways and validate clinically-relevant biomarkers. They also develop multiplex biomarker assays for tissue phenotyping and digital pathology, driving personalized medicine. Ultivue is headquartered in Cambridge, MA and offers a collaborative work environment with opportunities for talented individuals to contribute their passion, expertise, and creativity to solving problems that matter. Open positions can be found on their website.
Contacts

Contact Email

Social url

Legal Names

Legal name

Ultivue, Inc.
Similar Companies
1000
CellPrint Biotechnology

CellPrint Biotechnology

CellPrint Biotechnology conducts customized studies in drug discovery and diagnostics for partners.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cleveland, OH, USA
Kryptos Biotechnologies

Kryptos Biotechnologies

Kryptos Biotechnologies simplifies biology for clinicians and scientists.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Life Science, Health Care

Location

Hayward, CA, USA

total rounds

4

total raised

$21.8M
ConquerX

ConquerX

ConquerX is a biotechnology company that offers innovative molecular profiling solutions for clinical trials in precision medicine.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boston, MA, USA

total rounds

2

total raised

$81.87K
AYOXXA

AYOXXA

AYOXXA is a biotech company that commercializes innovative technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Analytics, Health Care

Location

Cologne, Germany

total rounds

4

total raised

$14.97M

Financials

Funding Rounds
6
3

Number of Funding Rounds

$110.58M

Money Raised

Their latest funding was raised on 25.07.2024. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
25.07.2024
$3.32M
Northpond Ventures

Northpond Ventures

Northpond Ventures is a science-driven venture capital firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Bethesda, MD, USA

count Of Investments

112

count Of Exists

4
Northpond Ventures

Northpond Ventures

Northpond Ventures is a science-driven venture capital firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Bethesda, MD, USA

count Of Investments

112

count Of Exists

4
Co-Investors
Investors
11
3

Number of lead investors

11

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series A, Series B, Series C, Series D
No
Series C
ARCH Venture Partners

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that specializes in investing in early-stage technology companies in the United States.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Chicago, IL, USA

count Of Investments

358

count Of Exists

61
Keith Crandell

Keith Crandell

Keith L. Crandell is the Co - Founder & Managing Director, ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. Mr. Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. He was also responsible for ARCH's investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), Teach.com (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. He is a Director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, Ciespace. Mr. Crandell also serves as a Director of the Illinois Venture Capital Association. Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc. He holds an M.B.A. from The University of Chicago. An M.S. in Chemistry from the University of Texas at Arlington. B.S. in Chemistry and Mathematics from St. Lawrence University.

current job

ARCH Venture Partners
ARCH Venture Partners
Northpond Ventures

Northpond Ventures

Northpond Ventures is a science-driven venture capital firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Bethesda, MD, USA

count Of Investments

112

count Of Exists

4
Sharon Kedar

Sharon Kedar

current job

Northpond Ventures
Northpond Ventures
Yonghua Capital

Yonghua Capital

Yongyong Investment specializes in equity investment management through its subsidiary Shanghai Chung Hua Investment Management.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance, Venture Capital

Location

Shanghai, China

count Of Investments

136

count Of Exists

3

People

Founders
3
Ralf Jungmann
Ralf Jungmann

Ralf Jungmann

current job

Ultivue
Ultivue

organization founded

1

Ralf Jungmann

Peng Yin
Peng Yin

Peng Yin

Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Co-Founder, Director at Torus Biosystems.

current job

Spear Bio
Spear Bio

organization founded

3

Peng Yin

David R. Walt
David R. Walt

David R. Walt

David is Professor in the Department of Pathology, Brigham and Women’s Hospital and Wyss Institute for Biologically Inspired Engineering, and is a Howard Hughes Medical Institute Professor. David is the Scientific Founder of Illumina Inc. and Quanterix Corp and has co-founded several other life sciences startups. David has published over 300 peer-reviewed papers and has over 75 issued US patents. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules including the American Chemical Society Kathryn C. Hach Award for Entrepreneurial Success, Ralph Adams Award in Bioanalytical Chemistry, the American Chemical Society Gustavus John Esselen Award, Analytical Chemistry Spectrochemical Analysis Award, the Pittsburgh Analytical Chemistry Award, and the ACS National Award for Creative Invention. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He received a BS in Chemistry from the University of Michigan and a PhD in Chemical Biology from SUNY at Stony Brook, and did postdoctoral studies at MIT.

current job

Ultivue
Ultivue

count Of Investments

7

David R. Walt

Employee Profiles
16
Florian Leiss

Florian Leiss

VP Digital Health Strategies

Keith Wharton

Keith Wharton

VP Medical Director

James Drummey

James Drummey

Vice President, Products and Quality

Thomas Huff

Associate director, commercial operations

Amanda Bares

Senior scientist

Barry Lynch

Commercial director

Pamela Guy

Senior manager intellectual property

Louis Levy

Director of corporate and business development at ultivue, inc

Activity

Recent News
2
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range